These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21376716)

  • 1. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells.
    Cerquetti L; Sampaoli C; Amendola D; Bucci B; Masuelli L; Marchese R; Misiti S; De Venanzi A; Poggi M; Toscano V; Stigliano A
    Exp Cell Res; 2011 Jun; 317(10):1397-410. PubMed ID: 21376716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
    Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
    Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
    Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins.
    Wu JS; Lin TN; Wu KK
    J Cell Physiol; 2009 Jul; 220(1):58-71. PubMed ID: 19229877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
    Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
    Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
    Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
    Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
    Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
    Vitale G; Zappavigna S; Marra M; Dicitore A; Meschini S; Condello M; Arancia G; Castiglioni S; Maroni P; Bendinelli P; Piccoletti R; van Koetsveld PM; Cavagnini F; Budillon A; Abbruzzese A; Hofland LJ; Caraglia M
    Biotechnol Adv; 2012; 30(1):169-84. PubMed ID: 21871555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
    Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
    Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
    Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
    Tencer L; Burgermeister E; Ebert MP; Liscovitch M
    Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.
    Liu DC; Zang CB; Liu HY; Possinger K; Fan SG; Elstner E
    Acta Pharmacol Sin; 2004 Oct; 25(10):1312-9. PubMed ID: 15456533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
    Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
    Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
    Sun WH; Chen GS; Ou XL; Yang Y; Luo C; Zhang Y; Shao Y; Xu HC; Xiao B; Xue YP; Zhou SM; Zhao QS; Ding GX
    Cancer Lett; 2009 Mar; 275(2):247-55. PubMed ID: 19056168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
    Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
    Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.